Pages that link to "Item:Q3078854"
From MaRDI portal
The following pages link to Dose-Finding Designs for HIV Studies (Q3078854):
Displaying 21 items.
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs (Q70261) (← links)
- On generalized multinomial models and joint percentile estimation (Q393556) (← links)
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
- Continual reassessment and related dose-finding designs (Q903292) (← links)
- Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials (Q2320854) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
- Adaptive designs for dose-finding based on efficacy-toxicity response (Q2492921) (← links)
- Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion (Q2893431) (← links)
- Sequential Methods in Multi-Arm Clinical Trials (Q3068083) (← links)
- Directed Walk Designs for Dose-Response Problems with Competing Failure Modes (Q3079102) (← links)
- Dynamic calibration of pharmacokinetic parameters in dose-finding studies (Q3303574) (← links)
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524) (← links)
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates (Q3549405) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- Patient-specific dose finding in seamless phase I/II clinical trials (Q5043686) (← links)
- Simple benchmark for complex dose finding studies (Q5170208) (← links)
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers (Q5450494) (← links)
- Up-and-Down Designs for Selecting the Dose with Maximum Success Probability (Q5458029) (← links)
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
